Pacific Biosciences of California (PACB) - Total Liabilities
Based on the latest financial reports, Pacific Biosciences of California (PACB) has total liabilities worth $780.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pacific Biosciences of California - Total Liabilities Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's total liabilities have evolved over time, based on quarterly financial data. See Pacific Biosciences of California short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Pacific Biosciences of California Competitors by Total Liabilities
The table below lists competitors of Pacific Biosciences of California ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lavvi Empreendimentos Imobiliários S.A
SA:LAVV3
|
Brazil | R$2.20 Billion |
|
Shandong Synthesis Electronic Technology Co Ltd
SHE:300479
|
China | CN¥950.14 Million |
|
Shenzhen Liantronics
SHE:300269
|
China | CN¥643.66 Million |
|
Johnson Controls - Hitachi Air Conditioning India Limited
NSE:JCHAC
|
India | Rs7.29 Billion |
|
MK Electron Co. Ltd
KQ:033160
|
Korea | ₩1.48 Trillion |
|
Malteries Franco-Belges Société Anonyme
PA:MALT
|
France | €30.52 Million |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
F:GU5
|
Germany | €47.87 Billion |
|
African Gold Ltd
AU:A1G
|
Australia | AU$3.23 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Pacific Biosciences of California's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Pacific Biosciences of California.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 329.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pacific Biosciences of California's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pacific Biosciences of California (2008–2025)
The table below shows the annual total liabilities of Pacific Biosciences of California from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $778.73 Million | +3.30% |
| 2024-12-31 | $753.85 Million | -27.84% |
| 2023-12-31 | $1.04 Billion | -13.24% |
| 2022-12-31 | $1.20 Billion | -0.97% |
| 2021-12-31 | $1.22 Billion | +1449.24% |
| 2020-12-31 | $78.49 Million | -15.66% |
| 2019-12-31 | $93.07 Million | +65.56% |
| 2018-12-31 | $56.21 Million | -3.05% |
| 2017-12-31 | $57.98 Million | +8.95% |
| 2016-12-31 | $53.22 Million | -7.56% |
| 2015-12-31 | $57.57 Million | -17.26% |
| 2014-12-31 | $69.57 Million | +3.83% |
| 2013-12-31 | $67.00 Million | +230.06% |
| 2012-12-31 | $20.30 Million | -24.40% |
| 2011-12-31 | $26.85 Million | +3.76% |
| 2010-12-31 | $25.88 Million | -90.70% |
| 2009-12-31 | $278.22 Million | +34.73% |
| 2008-12-31 | $206.50 Million | -- |
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more